Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.
Blood tumour DNA tests identify bladder cancer patients at high risk of progression better than current staging tools.
Aydogdu et al. demonstrate in a prospective cohort that serial circulating tumour DNA measurement identifies non-muscle-invasive bladder cancer patients at elevated risk of pathological upstaging to muscle-invasive disease and early recurrence, with performance superior to standard clinical risk stratification tools. Published in BJU International, this study supports integrating longitudinal ctDNA surveillance into NMIBC monitoring protocols to guide treatment intensification decisions in high-risk patients.
What the study was
- Study design
- Prospective longitudinal cohort study
- Population
- Non-muscle-invasive bladder cancer patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- BJU Int
Why it surfaced
Prospective longitudinal ctDNA study in BJU Int with practice-changing potential for NMIBC surveillance; directly relevant to T3 early cancer detection and liquid biopsy core topic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.